|
1.Oppenheimer JH, Schwartz HL, Mariash CN, Kinlaw WB, Wong NC, Freake HC 1987 Advances in our understanding of thyroid hormone action at the cellular level. Endocr Rev 8:288-308
2.Yen PM 2001 Physiological and molecular basis of thyroid hormone action. Physiol Rev 81:1097-142
3.Evans RM 1988 The steroid and thyroid hormone receptor superfamily. Science 240:889-95
4.Lee DY, Hayes JJ, Pruss D, Wolffe AP 1993 A positive role for histone acetylation in transcription factor access to nucleosomal DNA. Cell 72:73-84
5.Alland L, Muhle R, Hou H, Jr., Potes J, Chin L, Schreiber-Agus N, DePinho RA 1997 Role for N-CoR and histone deacetylase in Sin3-mediated transcriptional repression. Nature 387:49-55
6.Sap J, Munoz A, Damm K, Goldberg Y, Ghysdael J, Leutz A, Beug H, Vennstrom B 1986 The c-erb-A protein is a high-affinity receptor for thyroid hormone. Nature 324:635-40
7.Brent GA, Dunn MK, Harney JW, Gulick T, Larsen PR, Moore DD 1989 Thyroid hormone aporeceptor represses T3-inducible promoters and blocks activity of the retinoic acid receptor. New Biol 1:329-36
8.Graupner G, Wills KN, Tzukerman M, Zhang XK, Pfahl M 1989 Dual regulatory role for thyroid-hormone receptors allows control of retinoic-acid receptor activity. Nature 340:653-6
9.Wu Y, Koenig RJ 2000 Gene regulation by thyroid hormone. Trends Endocrinol Metab 11:207-11
10.Wagner RL, Apriletti JW, McGrath ME, West BL, Baxter JD, Fletterick RJ 1995 A structural role for hormone in the thyroid hormone receptor. Nature 378:690-7
11.Chakravarti D, LaMorte VJ, Nelson MC, Nakajima T, Schulman IG, Juguilon H, Montminy M, Evans RM 1996 Role of CBP/P300 in nuclear receptor signalling. Nature 383:99-103
12.Feng W, Ribeiro RC, Wagner RL, Nguyen H, Apriletti JW, Fletterick RJ, Baxter JD, Kushner PJ, West BL 1998 Hormone-dependent coactivator binding to a hydrophobic cleft on nuclear receptors. Science 280:1747-9
13.Torchia J, Glass C, Rosenfeld MG 1998 Co-activators and co-repressors in the integration of transcriptional responses. Curr Opin Cell Biol 10:373-83
14.Zhang XK, Hoffmann B, Tran PB, Graupner G, Pfahl M 1992 Retinoid X receptor is an auxiliary protein for thyroid hormone and retinoic acid receptors. Nature 355:441-6
15.Schrader M, Muller KM, Nayeri S, Kahlen JP, Carlberg C 1994 Vitamin D3-thyroid hormone receptor heterodimer polarity directs ligand sensitivity of transactivation. Nature 370:382-6
16.Bogazzi F, Hudson LD, Nikodem VM 1994 A novel heterodimerization partner for thyroid hormone receptor. Peroxisome proliferator-activated receptor. J Biol Chem 269:11683-6
17.Wahlstrom GM, Sjoberg M, Andersson M, Nordstrom K, Vennstrom B 1992 Binding characteristics of the thyroid hormone receptor homo- and heterodimers to consensus AGGTCA repeat motifs. Mol Endocrinol 6:1013-22
18.Shupnik MA, Ardisson LJ, Meskell MJ, Bornstein J, Ridgway EC 1986 Triiodothyronine (T3) regulation of thyrotropin subunit gene transcription is proportional to T3 nuclear receptor occupancy. Endocrinology 118:367-71
19.Chatterjee VK, Lee JK, Rentoumis A, Jameson JL 1989 Negative regulation of the thyroid-stimulating hormone alpha gene by thyroid hormone: receptor interaction adjacent to the TATA box. Proc Natl Acad Sci U S A 86:9114-8
20.Bodenner DL, Mroczynski MA, Weintraub BD, Radovick S, Wondisford FE 1991 A detailed functional and structural analysis of a major thyroid hormone inhibitory element in the human thyrotropin beta-subunit gene. J Biol Chem 266:21666-73
21.Hollenberg AN, Monden T, Flynn TR, Boers ME, Cohen O, Wondisford FE 1995 The human thyrotropin-releasing hormone gene is regulated by thyroid hormone through two distinct classes of negative thyroid hormone response elements. Mol Endocrinol 9:540-50
22.Tagami T, Madison LD, Nagaya T, Jameson JL 1997 Nuclear receptor corepressors activate rather than suppress basal transcription of genes that are negatively regulated by thyroid hormone. Mol Cell Biol 17:2642-8
23.Tagami T, Park Y, Jameson JL 1999 Mechanisms that mediate negative regulation of the thyroid-stimulating hormone alpha gene by the thyroid hormone receptor. J Biol Chem 274:22345-53
24.Lazar MA 2003 Thyroid hormone action: a binding contract. J Clin Invest 112:497-9
25.Kopp P, Kitajima K, Jameson JL 1996 Syndrome of resistance to thyroid hormone: insights into thyroid hormone action. Proc Soc Exp Biol Med 211:49-61
26.Ferrari AC, Seuanez HN, Hanash SM, Atweh GF 1990 A gene that encodes for a leukemia-associated phosphoprotein (p18) maps to chromosome bands 1p35-36.1. Genes Chromosomes Cancer 2:125-9
27.Okazaki T, Yoshida BN, Avraham KB, Wang H, Wuenschell CW, Jenkins NA, Copeland NG, Anderson DJ, Mori N 1993 Molecular diversity of the SCG10/stathmin gene family in the mouse. Genomics 18:360-73
28.Ozon S, Byk T, Sobel A 1998 SCLIP: a novel SCG10-like protein of the stathmin family expressed in the nervous system. J Neurochem 70:2386-96
29.Ozon S, Maucuer A, Sobel A 1997 The stathmin family -- molecular and biological characterization of novel mammalian proteins expressed in the nervous system. Eur J Biochem 248:794-806
30.Cassimeris L 2002 The oncoprotein 18/stathmin family of microtubule destabilizers. Curr Opin Cell Biol 14:18-24
31.Curmi PA, Gavet O, Charbaut E, Ozon S, Lachkar-Colmerauer S, Manceau V, Siavoshian S, Maucuer A, Sobel A 1999 Stathmin and its phosphoprotein family: general properties, biochemical and functional interaction with tubulin. Cell Struct Funct 24:345-57
32.le Gouvello S, Manceau V, Sobel A 1998 Serine 16 of stathmin as a cytosolic target for Ca2+/calmodulin-dependent kinase II after CD2 triggering of human T lymphocytes. J Immunol 161:1113-22
33.Marklund U, Larsson N, Brattsand G, Osterman O, Chatila TA, Gullberg M 1994 Serine 16 of oncoprotein 18 is a major cytosolic target for the Ca2+/calmodulin-dependent kinase-Gr. Eur J Biochem 225:53-60
34.Melander Gradin H, Marklund U, Larsson N, Chatila TA, Gullberg M 1997 Regulation of microtubule dynamics by Ca2+/calmodulin-dependent kinase IV/Gr-dependent phosphorylation of oncoprotein 18. Mol Cell Biol 17:3459-67
35.Beretta L, Dubois MF, Sobel A, Bensaude O 1995 Stathmin is a major substrate for mitogen-activated protein kinase during heat shock and chemical stress in HeLa cells. Eur J Biochem 227:388-95
36.Leighton IA, Curmi P, Campbell DG, Cohen P, Sobel A 1993 The phosphorylation of stathmin by MAP kinase. Mol Cell Biochem 127-128:151-6
37.Marklund U, Brattsand G, Shingler V, Gullberg M 1993 Serine 25 of oncoprotein 18 is a major cytosolic target for the mitogen-activated protein kinase. J Biol Chem 268:15039-47
38.Beretta L, Dobransky T, Sobel A 1993 Multiple phosphorylation of stathmin. Identification of four sites phosphorylated in intact cells and in vitro by cyclic AMP-dependent protein kinase and p34cdc2. J Biol Chem 268:20076-84
39.Brattsand G, Marklund U, Nylander K, Roos G, Gullberg M 1994 Cell-cycle-regulated phosphorylation of oncoprotein 18 on Ser16, Ser25 and Ser38. Eur J Biochem 220:359-68
40.Luo XN, Mookerjee B, Ferrari A, Mistry S, Atweh GF 1994 Regulation of phosphoprotein p18 in leukemic cells. Cell cycle regulated phosphorylation by p34cdc2 kinase. J Biol Chem 269:10312-8
41.Marklund U, Osterman O, Melander H, Bergh A, Gullberg M 1994 The phenotype of a "Cdc2 kinase target site-deficient" mutant of oncoprotein 18 reveals a role of this protein in cell cycle control. J Biol Chem 269:30626-35
42.Belmont LD, Mitchison TJ 1996 Identification of a protein that interacts with tubulin dimers and increases the catastrophe rate of microtubules. Cell 84:623-31
43.Jourdain L, Curmi P, Sobel A, Pantaloni D, Carlier MF 1997 Stathmin: a tubulin-sequestering protein which forms a ternary T2S complex with two tubulin molecules. Biochemistry 36:10817-21
44.Howell B, Larsson N, Gullberg M, Cassimeris L 1999 Dissociation of the tubulin-sequestering and microtubule catastrophe-promoting activities of oncoprotein 18/stathmin. Mol Biol Cell 10:105-18
45.Gigant B, Curmi PA, Martin-Barbey C, Charbaut E, Lachkar S, Lebeau L, Siavoshian S, Sobel A, Knossow M 2000 The 4 A X-ray structure of a tubulin:stathmin-like domain complex. Cell 102:809-16
46.Wallon G, Rappsilber J, Mann M, Serrano L 2000 Model for stathmin/OP18 binding to tubulin. Embo J 19:213-22
47.Rubin CI, Atweh GF 2004 The role of stathmin in the regulation of the cell cycle. J Cell Biochem 93:242-50
48.Marklund U, Larsson N, Gradin HM, Brattsand G, Gullberg M 1996 Oncoprotein 18 is a phosphorylation-responsive regulator of microtubule dynamics. Embo J 15:5290-8
49.Larsson N, Marklund U, Gradin HM, Brattsand G, Gullberg M 1997 Control of microtubule dynamics by oncoprotein 18: dissection of the regulatory role of multisite phosphorylation during mitosis. Mol Cell Biol 17:5530-9
50.Iancu C, Mistry SJ, Arkin S, Wallenstein S, Atweh GF 2001 Effects of stathmin inhibition on the mitotic spindle. J Cell Sci 114:909-16
51.Mistry SJ, Atweh GF 2002 Role of stathmin in the regulation of the mitotic spindle: potential applications in cancer therapy. Mt Sinai J Med 69:299-304
52.Gavet O, Ozon S, Manceau V, Lawler S, Curmi P, Sobel A 1998 The stathmin phosphoprotein family: intracellular localization and effects on the microtubule network. J Cell Sci 111 ( Pt 22):3333-46
53.Mistry SJ, Atweh GF 2001 Stathmin inhibition enhances okadaic acid-induced mitotic arrest: a potential role for stathmin in mitotic exit. J Biol Chem 276:31209-15
54.Koppel J, Loyer P, Maucuer A, Rehak P, Manceau V, Guguen-Guillouzo C, Sobel A 1993 Induction of stathmin expression during liver regeneration. FEBS Lett 331:65-70
55.Melhem RF, Strahler JR, Hailat N, Zhu XX, Hanash SM 1991 Involvement of OP18 in cell proliferation. Biochem Biophys Res Commun 179:1649-55
56.Roos G, Brattsand G, Landberg G, Marklund U, Gullberg M 1993 Expression of oncoprotein 18 in human leukemias and lymphomas. Leukemia 7:1538-46
57.Friedrich B, Gronberg H, Landstrom M, Gullberg M, Bergh A 1995 Differentiation-stage specific expression of oncoprotein 18 in human and rat prostatic adenocarcinoma. Prostate 27:102-9
58.Bieche I, Lachkar S, Becette V, Cifuentes-Diaz C, Sobel A, Lidereau R, Curmi PA 1998 Overexpression of the stathmin gene in a subset of human breast cancer. Br J Cancer 78:701-9
59.Brattsand G 2000 Correlation of oncoprotein 18/stathmin expression in human breast cancer with established prognostic factors. Br J Cancer 83:311-8
60.Curmi PA, Nogues C, Lachkar S, Carelle N, Gonthier MP, Sobel A, Lidereau R, Bieche I 2000 Overexpression of stathmin in breast carcinomas points out to highly proliferative tumours. Br J Cancer 82:142-50
61.Price DK, Ball JR, Bahrani-Mostafavi Z, Vachris JC, Kaufman JS, Naumann RW, Higgins RV, Hall JB 2000 The phosphoprotein Op18/stathmin is differentially expressed in ovarian cancer. Cancer Invest 18:722-30
62.Chen G, Wang H, Gharib TG, Huang CC, Thomas DG, Shedden KA, Kuick R, Taylor JM, Kardia SL, Misek DE, Giordano TJ, Iannettoni MD, Orringer MB, Hanash SM, Beer DG 2003 Overexpression of oncoprotein 18 correlates with poor differentiation in lung adenocarcinomas. Mol Cell Proteomics 2:107-16
63.Li C, Tan YX, Zhou H, Ding SJ, Li SJ, Ma DJ, Man XB, Hong Y, Zhang L, Li L, Xia QC, Wu JR, Wang HY, Zeng R 2005 Proteomic analysis of hepatitis B virus-associated hepatocellular carcinoma: Identification of potential tumor markers. Proteomics 5:1125-39
64.Yuan RH, Jeng YM, Chen HL, Lai PL, Pan HW, Hsieh FJ, Lin CY, Lee PH, Hsu HC 2006 Stathmin overexpression cooperates with p53 mutation and osteopontin overexpression, and is associated with tumour progression, early recurrence, and poor prognosis in hepatocellular carcinoma. J Pathol
65.Lin KH, Shieh HY, Hsu HC 2000 Negative regulation of the antimetastatic gene Nm23-H1 by thyroid hormone receptors. Endocrinology 141:2540-7
66.Shih CH, Chen SL, Yen CC, Huang YH, Chen CD, Lee YS, Lin KH 2004 Thyroid hormone receptor-dependent transcriptional regulation of fibrinogen and coagulation proteins. Endocrinology 145:2804-14
67.Luo XN, Arcasoy MO, Brickner HE, Mistry S, Schechter AD, Atweh GF 1991 Regulated expression of p18, a major phosphoprotein of leukemic cells. J Biol Chem 266:21004-10
68.Hanash SM, Strahler JR, Kuick R, Chu EH, Nichols D 1988 Identification of a polypeptide associated with the malignant phenotype in acute leukemia. J Biol Chem 263:12813-5
69.Yen CC, Huang YH, Liao CY, Liao CJ, Cheng WL, Chen WJ, Lin KH 2006 Mediation of the inhibitory effect of thyroid hormone on proliferation of hepatoma cells by transforming growth factor-beta. J Mol Endocrinol 36:9-21
70.Ozon S, Guichet A, Gavet O, Roth S, Sobel A 2002 Drosophila stathmin: a microtubule-destabilizing factor involved in nervous system formation. Mol Biol Cell 13:698-710
71.Jin K, Mao XO, Cottrell B, Schilling B, Xie L, Row RH, Sun Y, Peel A, Childs J, Gendeh G, Gibson BW, Greenberg DA 2004 Proteomic and immunochemical characterization of a role for stathmin in adult neurogenesis. Faseb J 18:287-99
72.Baldassarre G, Belletti B, Nicoloso MS, Schiappacassi M, Vecchione A, Spessotto P, Morrione A, Canzonieri V, Colombatti A 2005 p27(Kip1)-stathmin interaction influences sarcoma cell migration and invasion. Cancer Cell 7:51-63
73.Polzin RG, Benlhabib H, Trepel J, Herrera JE 2004 E2F sites in the Op18 promoter are required for high level of expression in the human prostate carcinoma cell line PC-3-M. Gene 341:209-18
74.Ahn J, Murphy M, Kratowicz S, Wang A, Levine AJ, George DL 1999 Down-regulation of the stathmin/Op18 and FKBP25 genes following p53 induction. Oncogene 18:5954-8
75.Murphy M, Ahn J, Walker KK, Hoffman WH, Evans RM, Levine AJ, George DL 1999 Transcriptional repression by wild-type p53 utilizes histone deacetylases, mediated by interaction with mSin3a. Genes Dev 13:2490-501
76.Johnsen JI, Aurelio ON, Kwaja Z, Jorgensen GE, Pellegata NS, Plattner R, Stanbridge EJ, Cajot JF 2000 p53-mediated negative regulation of stathmin/Op18 expression is associated with G(2)/M cell-cycle arrest. Int J Cancer 88:685-91
77.Lohr K, Moritz C, Contente A, Dobbelstein M 2003 p21/CDKN1A mediates negative regulation of transcription by p53. J Biol Chem 278:32507-16
78.Yang Q, Yoshimura G, Mori I, Sakurai T, Kakudo K 2002 Chromosome 3p and breast cancer. J Hum Genet 47:453-9
79.Williams GR, Bland R, Sheppard MC 1994 Characterization of thyroid hormone (T3) receptors in three osteosarcoma cell lines of distinct osteoblast phenotype: interactions among T3, vitamin D3, and retinoid signaling. Endocrinology 135:2375-85
80.Lebel JM, Dussault JH, Puymirat J 1994 Overexpression of the beta 1 thyroid receptor induces differentiation in neuro-2a cells. Proc Natl Acad Sci U S A 91:2644-8
81.Puzianowska-Kuznicka M, Krystyniak A, Madej A, Cheng SY, Nauman J 2002 Functionally impaired TR mutants are present in thyroid papillary cancer. J Clin Endocrinol Metab 87:1120-8
82.Silva JM, Dominguez G, Gonzalez-Sancho JM, Garcia JM, Silva J, Garcia-Andrade C, Navarro A, Munoz A, Bonilla F 2002 Expression of thyroid hormone receptor/erbA genes is altered in human breast cancer. Oncogene 21:4307-16
83.Li Z, Meng ZH, Chandrasekaran R, Kuo WL, Collins CC, Gray JW, Dairkee SH 2002 Biallelic inactivation of the thyroid hormone receptor beta1 gene in early stage breast cancer. Cancer Res 62:1939-43
84.Lin KH, Zhu XG, Shieh HY, Hsu HC, Chen ST, McPhie P, Cheng SY 1996 Identification of naturally occurring dominant negative mutants of thyroid hormone alpha 1 and beta 1 receptors in a human hepatocellular carcinoma cell line. Endocrinology 137:4073-81
85.Lin KH, Shieh HY, Chen SL, Hsu HC 1999 Expression of mutant thyroid hormone nuclear receptors in human hepatocellular carcinoma cells. Mol Carcinog 26:53-61
|